Cassava Sciences, Inc. (SAVA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
7801 North Capital of Texas Highway
Austin, TX 78731
United States of America (the)
Phone
512 501 2444
Sector
Healthcare
Industry
Biotechnology
Employees
30
First IPO Date
July 14, 2000
| Name | Title | Pay | Year Born |
| Richard Jon Barry | Chief Executive Officer, President & Director | 319,375 | 1959 |
| Christopher Cook | Chief Operating & Legal Officer | 425,000 | 1964 |
| Joseph Hulihan | Chief Medical Officer | 499,000 | 1956 |
| Eric J. Schoen | Chief Financial Officer | 725,000 | 1968 |
| Angélique Bordey | Senior Vice President of Neuroscience | 0 | N/A |
| Jack Moore | Senior Vice President of Clinical Development | 0 | N/A |
| Freda Nassif | Chief Business Officer & Chief Commercial Officer | 0 | 1976 |
| George Thornton | Senior Vice President of Technology | 0 | N/A |
| Jaren Landen | Chief Clinical Development Officer | 0 | N/A |
| Michael Zamloot | Senior Vice President of Technical Operations | 0 | N/A |
Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.